Actively Recruiting

Phase Not Applicable
All Genders
Healthy Volunteers
NCT06111950

Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes

Led by Hospices Civils de Lyon · Updated on 2024-10-09

45

Participants Needed

6

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In the human genome, about 750 genes contain one intron excised by the minor spliceosome. These genes are named U12 genes, and these introns, minor or U12 introns. The minor spliceosome comprises its own set of snRNAs, among which U4atac. Its non-coding gene, RNU4ATAC, has been found mutated in Taybi-Linder (TALS), Roifman (RFMN) and Lowry-Wood syndromes (LWS). These rare developmental disorders associate ante- and post-natal growth retardation, microcephaly, skeletal dysplasia, intellectual disability, retinal dystrophy and immunodeficiency. Their physiopathological mechanisms remain unsolved: the number of U12 genes involved, their identity and function, or the cellular mechanisms impacted by the splicing defect, are still unknown. The hypothesis of the study is that U12 genes coding for primary cilia components are particularly sensitive to minor splicing defects caused by RNU4ATAC mutations. Indeed, a child showing signs of TALS but negative for RNU4ATAC was found to carry a homozygous variant in the RTTN gene, coding for the rotatin protein located at the centrosome and the base of the primary cilia and playing a role in maintaining these structures. In addition, bi-allelic RNU4ATAC mutations were identified in five patients presenting with traits suggestive of the Joubert syndrome (JBTS), a well-characterized ciliopathy. These patients also present with traits typical of TALS/RFMN/LWS. To better understand the causes of these pathologies, a cohort of patients with syndromes associated with bi-allele mutations of the RNU4ATAC or RTTN gene will be gathered, in order to conduct studies on the cells of these patients. Blood samples will be taken, as well as skin biopsies, if possible. These samples will be used to create induced pluripotent stem cell lines. Blood samples will also be collected from the parents of RNU4ATAC patients, to eliminate in transcriptomic analyses expression variations due to differences in genetic background. Biopsies of skin, muscle and brain tissue will be collected on foetuses carrying two-allele RNU4ATAC or RTTN mutations whose parents have had a miscarriage or have chosen to have a medical abortion. The biological samples collected will be used to study the transcription level of U12 genes, the splicing of their pre-messenger RNA, their main cellular functions, and the structural characteristics of tissues and cells.

CONDITIONS

Official Title

Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes

Who Can Participate

All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis with Taybi-Linder, Roifman, Lowry-Wood syndrome or other related conditions
  • Male or female of any age
  • Presence of bi-allelic mutations in RNU4ATAC or RTTN genes
  • Written consent from parents or legal guardians
  • Affiliation to a Social Security scheme
  • Healthy parents of patients with mono-allelic RNU4ATAC mutations who are adults
  • Written consent from healthy participants
  • Parents who have had a medical termination of pregnancy or miscarriage with fetus having bi-allelic mutations
  • Written parental consent for fetal sample collection
  • Affiliation to a Social Security scheme
Not Eligible

You will not qualify if you...

  • Participation in another research study with an ongoing exclusion period

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Centre de référence des anomalies du développement et syndromes malformatifs du Sud-Ouest Occitanie Réunion, CHU de Bordeaux-GH Pellegrin

Bordeaux, France, 33000

Not Yet Recruiting

2

Centre de référence anomalies du développement de Lyon, Hôpital Femme Mère Enfant

Bron, France, 69500

Actively Recruiting

3

Centre de référence des anomalies du développement et syndromes malformatifs de l'Est, CHU de DIJON

Dijon, France, 9000

Not Yet Recruiting

4

Centre de référence des anomalies du développement et syndromes malformatifs de l'inter région Nord-Ouest, Hôpital J de Flandre

Lille, France, 59000

Not Yet Recruiting

5

Unité Fonctionelle d'embryo-fœtopathologie, Hôpital Necker-Enfants Malades

Paris, France, 75743

Not Yet Recruiting

6

Centre de référence des anomalies du développement et syndromes malformatifs de l'Ouest, Hôpital Sud

Rennes, France, 35000

Not Yet Recruiting

Loading map...

Research Team

S

Sylvie MAZOYER, Dr

CONTACT

P

Patrick EDERY, Pr

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here